JGC
MRTX

J. Goldman & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

J. Goldman & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,700
Closed -$1.19M – 474
2021
Q3 		$1.19M Buy
+6,700
New +$1.08M 0.06% 233

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

J. Goldman & Co's MRTX Position: Q4 2021 in Review

J. Goldman & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 2,606 shares — an estimated $461K sold.

J. Goldman & Co first reported a position in MRTX in Q2 2019 and held it in 3 quarters. The position peaked at $2.33M in Q2 2019. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

  • J. Goldman & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • J. Goldman & Co sold 2,606 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $461K.
  • J. Goldman & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • J. Goldman & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $2.33M in Q2 2019.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.